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Abstract
The renin angiotensin system (RAS) through its hormone angiotensin (AngII) and the
protease thrombin are two major physiological regulators of vascular and renal
functions. RAS is involved in the regulation of blood pressure and water-electrolytes
hemostasis, while thrombin has a crucial role in platelets activation and thrombosis.
The interplay between these two systems at the physiological and the
pathophysiological levels has been documented in many studies. However, such an
interplay at the pharmacological level between the AngII and thrombin receptors still
has not been explored. Our study aimed to explore the interplay between the AngII
type 1 receptor (AT1R) and the thrombin protease-activated receptor (PAR1), which
both belong to the G protein-coupled receptors (GPCR) family, using transfected
human embryonic kidney (HEK293) cells. For this various bioluminescence resonance
energy transfer (BRET) technology-based analytical and biochemical assays were
used. BRET saturation and co-immunoprecipitation demonstrated the physical
interaction between AT1R and PAR1 indicating their heterodimerization in vitro.
Moreover, dose response and real-time kinetic experiments revealed a functional
AT1R-PAR1 interaction characterized by a positive allosteric modulation and
transactivation of AT1R activity by PAR1 towards its coupling to Gαq protein, inositol
phosphate (IP1) pathway, and β-arrestin recruitment. This was contrasted with a transinhibition of AT1R internalization as well as its endosomal trafficking upon PAR1
activation. Together, our data demonstrated for the first time the physical and
functional interaction between AT1R and PAR1 which may constitute a molecular and
mechanistic rationale for the well-known interplay between RAS and thrombin. These
findings are of extreme importance in the field of drug discovery. Targeting the
pathological conditions involving RAS and thrombin opens promising perspectives for
the identification of selective and safer drugs by considering AT1R-PAR1
heterodimers as a potential druggable molecular entity.

Keywords: AngII, thrombin, G protein coupled receptor, AT1R, PAR1, BRET,
heterodimerization, allosteric modulation.
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)Title and Abstract (in Arabic

دراسة االرتباط والتفاعل ما بين مستقبالت هرمون األنجيوتينسين  2وأنزيم الثرومبين
الملخص

يُعدُّ كل من نظام الرنين-أنجيوتينسين عن طريق هرمونه ،األنجيوتينسين  )AngII( 2ونظام أنزيم
الثرومبين ( )thombinذوا أهمية بالغة في الحفاظ على توازن وصحة جهاز القلب واألوعية
الدموية ووظائف الكلى .حيث يعمل نظام الرنين-أنجيوتينسين على المحافظة على توازن ضغط
الدم و الماء واألمالح ،بينما يقوم أنزيم الثرومين بدور أساسي كعامل تخثر ومساعد على تنشيط
الصفائح الدموية .العديد من الدراسات وثّقت التفاعل ما بين هذين النظامين على مستوى
الفسيولوجيا وارتباط كالهما بالعديد من األمراض .لكن ،حتى اآلن لم تتم دراسة هذا التفاعل على
سعت دراستنا لفهم إن كان هذا التفاعل بين كل من
مستوى المستقبالت لهذين النظامين .لهذاَ ،
هذين النظامين يحدث على مستوى المستقبالت الخاصة بهم ،مستقبالت هرمون األنجيوتنسين 2
) (AT1Rومستقبالت أنزيم الثرومبين ( ،)PAR1واللذان ينتميان لعائلة المستقبالت المقترنة
ببروتين-ج وذلك باستخدام خاليا إنسانية من الكلى الجنينية ( )HEK293معدّلة جينيا ً بحيث تحتوى
على هذه المستقبالت .إلتمام هذه الدراسة قمنا باستخدام تقنية بريت ) (BRETوتقنيات كيميائية
حيوية .حيث أثبتت نتائجنا التقارب الجزيئي بين مستقبالت األنجيوتينسين  2ومستقبالت الثرومبين
باستخدام تقنية بريت للتشبُّع ( )BRET Saturation assayباإلضافة لتقنية الترسيب المناعي (Co-

) immunoprecipitationوالتي بدورها أ ّكدت أنهما مترابطان سويا ً ويشكالن مركبا ً في التجارب
المخبرية .إضافة إلى ذلك ،كل من تجارب الجرعة باإلستجابة ) (Dose Responseوتجارب
الحركية حقيقية الوقت ) ،(Real-Time Kineticsأثبتت بدورها تفاعل هذا الترابط وظيفيا ً
باالرتباط ببروتين-ج ) ،(Gαqتنشيط مسار إينوزيتول أحادي الفوسفات ) ،(IP1وتنشيط بروتينات
أريستين  (β-arrestin 2) 2حيث كان هذا عن طريق تنشيط مستقبالت األنجيوتينسين  2بواسطة
بيتا ّ
مستقبالت الثرومبين ) ،(Transactivationإضافة لكون مستقبل الثرومبين معدِّّل تفارغي إيجابي
) (positive allosteric modulatorلمستقبالت األنجيوتينسين .عالوة ً على ذلك ،أظهرت مستقبالت
الثرومبين تثبيط لإلدخال الخلوي لمستقبالت ألنجيوتينسين  2ومساراتها .دراستنا هذه أثبتت ألول
مرة التقارب الجزيئي والتفاعل الوظيفي بين مستقبالت األنجيوتينسين  2ومستقبالت الثرومبين،
والتي بدورها يمكن أن تكون السبب في التفاعل بين نظام الرنين-أنجيوتينسين والثرومبين .وتعد ُّ
هذه النتائج ذات أهمية كبيرة في مجال علم األدوية لعالج األمراض التي يلعبان فيها هذين النظامين
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دورا ً في تفاقهما ،بهدف الحصول على نتائج مبشرة الستكشاف أدوية ذات فعالية أكبر وآثار جانبية
أقل عن طريق أخذ هذا التفاعل على مستوى المستقبالت وترابطها بعين االعتبار.
مفاهيم البحث الرئيسية :نظام الرنين-أنجيوتينسين ،أنجيوتينسين  ،2ثرومبين ،المستقبالت
المرتبطة ببروتين ج ،مستقبالت هرمون األنجيوتنسين  ،2مستقبالت أنزيم الثرومبين ،تقنية
بريت ،الترابط بين المستقبالت ،معدِّّل تفارغي إيجابي أنزيم الثرومبين ،تقنية بريت .الترابط بين
المستقبالت ،معدِّّل تفارغي إيجابي.
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Chapter 1: Introduction
1.1 G Protein-Coupled Receptors (GPCRs)
GPCRs are seven-transmembrane receptors that bind to the heterotrimeric G protein
and mediate downstream signaling pathways controlling many biological responses
[1]. GPCRs have a classical structure composed of seven hydrophobic transmembrane
α-helices, extracellular N-terminus, and intracellular C-terminus [2], [3]. They are
classified into either five families based on the physiological features and sequence
homology named; rhodopsin, adhesion, secretin, glutamate, and frizzled or into four
classes; A, B, C, and F. Class A constitutes the largest family thus, carrying out various
functions. This family has a common ligand-binding pocket between the helices. Most
of these GPCRs have two conserved motifs that are important for protein stabilization
and/or G protein activation, NSXXNPXXY in helix VII and a DRY motif (Asp-ArgTyr) at the cytoplasmic border of helix III [2], [3]. Class B contains 47 receptors which
interact mostly with hormone-like peptides [2], [3]. Class C has 15 GPCRs that have
a ‘Venus flytrap’ N terminus composed of two lobes that close around the ligand, and
they commonly form dimers. While Class F has 11 receptors that activate Wnt
pathway. Around 800 different human genes encode for GPCRs. However, ~300 genes
of them encode for orphan GPCRs (with unknown function) [2], [3]. These GPCRs
are the receptors for many stimuli such as peptides, ions, hormones, neurotransmitters,
lipids, amines, and nucleotides [1], [4]. They represent one of the largest and most
diverse group of membrane receptors (~ 4% of the human genome) with incredible
array of functions in the human body [1], [4]. GPCRs regulate several physiological
responses including but not limited to taste, odor, pain, neurotransmission, blood
pressure, coagulation, and immune responses [5], [6]. In addition, GPCRs are involved
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in various pathophysiological situations such as cancer, hypertension, diabetes, viral
infections, and atherosclerosis [7]–[10]. Therefore, these receptors have a significant
contribution in drug discovery and the increased understanding of these receptors has
greatly influenced modern medicine, as more than 30% of all drugs in markets
nowadays are targeting GPCRs [11], [12].

Figure 1: GPCR activation and signaling.

1.2 GPCR Activation and Regulation
When an agonist binds to its GPCR, it induces conformational changes in the
intracellular region of the GPCR, which serves as a binding pocket for the guanine
nucleotide exchange factor GEF for G protein binding [2]. Agonist-activated GPCR,
facilitates the exchange of GDP (from inactive G protein) to GTP (active G protein),
hence the name of G proteins came. Then, the GTP bound α subunit dissociates from
the βγ subunits and G protein subunits undergo downstream signaling, each subunit
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regulates its effector proteins. As shown in Figure 1, α subunits have four subtypes
Gαi and Gαs inhibits and stimulates adenylyl cyclase (AC) respectively, Gαq activates
PLC, and Gα12/13 activates the Rho pathway, while the βγ dimer activates ion
channels and PLCβ [2], [4]. This stimulation of G proteins subunits of the first
messenger effectors (enzyme or ion channel) mediates the production of second
messenger molecules, entry of ions at the plasma membrane, and various kinases
activation as shown in Figure 1 [2], [4], [13]. In addition to this classical paradigm of
two parts; the GPCR and coupling to its G protein effector, which is oversimplified,
many GPCRs can bind to several G proteins and each subunit can activate different
signaling pathway. Moreover, GPCRs can also signal independently from G protein
(G protein independent signaling) through β-arrestin [2], [14]. These β-arrestinmediated signaling pathways are engaged in i) protein phosphatase 2 A
dephosphorylation of Akt, ii) inhibiting NF-κB, iii) anti-apoptosis, iv) extracellular
signal-regulated Kinas ERK- dependent stimulation of protein translation, among
others [15].
β-arrestins are multifunctional endocytic adaptors and signal transducer proteins that
bind to phosphorylated GPCRs, the phosphorylated GPCR serves as a substrate for βarrestin (Figure 2) [16]. GPCR kinases (GRK) phosphorylate GPCRs at specific sites
in the intracellular region and C-terminus, allowing β-arrestin binding mediating G
proteins inactivation/desensitization, GPCRs endocytosis and trafficking, and
promoting G protein–independent signaling by scaffolding other signaling proteins
[16]. This GRK-arrestin pathway is well known for GPCRs regulation by regulating
cellular second messengers production level [17]. Arrestins function is not limited to
GPCRs desensitization, they also function as endocytic adaptors, regulating the
delivery or removal of receptors from or to the plasma membrane (GPCRs trafficking)
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by linking GPCRs to clathrin-coated pits mediating their endosomal trafficking in
either early or late endosomes for membrane recycling or degradation, respectively
[18]. Moreover, β-arrestins are signal transducers and scaffolding adaptors linking
activated GPCRs to various scaffolding signaling pathways such as c-Raf-1 and c-Src
that activate MAPK/ERK pathway [16], [17]. To come closer again, MAPK/ERK
pathway can be activated dependently and independently from G protein [17]. G
protein dependent activation is mediated via Gαq-produced PKC, mediating rapid and
transient activation of nuclear ERK, which works on transcription factors controlling
cellular proliferation and differentiation. On the other hand, the G protein independent
activation of ERK via β-arrestin and other scaffolding proteins including Raf, is slow
and persistent and associated with controlling cellular motility, chemotaxis, and
apoptosis [17]. The discovery of this role for arrestins as signaling adaptors led to the
discovery of the concept of biased agonism. Biased signaling or functional selectivity
reflects the ability of a certain receptor to activate one signal transducer over another
like β-arrestin over G protein [15], [19]. The importance of biased signaling relies on
their crucial role in drug discovery. An example for this is the morphine binding to its
receptor, the µ-opioid receptor and signaling through G protein mediates the pain relief
effect, while the β-arrestin-dependent signaling apparently causes most of the side
effects [19].
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Figure 2: The role of β-arrestin in GPCR regulation [20].

1.3 Heterodimerization of GPCRs
Interactions between membrane receptors for intercellular communication have been
reported in many studies, mediating many pharmacological, physiological, and
pathophysiological roles. This is true for the two major families of receptors, G
protein-coupled receptors (GPCRs) and receptor tyrosine kinase (RTKs). These
receptors can function not only as monomer, several different signals are mediated by
the formation of complexes of dimers; two molecules of the same receptor
(homodimer) or two different receptors (heterodimer), as well as high-order oligomers
in living cells as a unique way for cellular communications between receptors.
Heterodimerization consists of physical and functional interactions between receptors
and has been reported for many GPCRs as well as RTKs (Table 1). Ferre et al. defined
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a receptor heteromer as “a macromolecular complex composed of at least two
(functional) receptor units (protomers) with biochemical properties that are
demonstrably different from those of its individual components” [21]. Classically, an
allosteric modulator, is a molecule that binds to a site other than the orthostatic binding
site, altering its function. However, in the case of GPCRs heterodimerization, one
protomer is acting as an allosteric modulator for the second protomer, altering its
functionality [14]. This altered functionality includes various consequences on the
receptor’s; i) Pharmacology, including altered selectivity to the agonist, antagonist,
with co-activation, co-inhibition reflecting the presence of a novel binding pocket in
the heterodimer, ii) Transactivation, the ligand-induced conformational change in one
protomer receptor, activates the second protomer, iii) Transinhibition, and iv) altered
trafficking and internalization compared to the single expression of the receptors [14],
[21] (Figure 3). Gomes et al. sorted GPCRs heterodimer formation into three criteria,
heterodimer should show: i) Colocalization and have physical interaction, ii) Distinct
properties such as unique signaling, and iii) Disruption of the heterodimer, alters its
properties [22]. The concept of heterodimerization has developed quickly due to its
extreme importance in the field of pharmaceutical manufacturing for the identification
of selective compounds with potentially less side-effects, considering the synergistic
and antagonistic interactions between drugs, as well as receptor-receptor
heterodimerization that may influence the drug-drug interaction at the clinical
molecular level [14], [22], [23].
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Figure 3: GPCR heterodimerization and its functional consequences [24].

1.4 The Renin-Angiotensin System (RAS) and its Receptors
The renin-Angiotensin system (RAS) is a network of hormones and receptors which
have a fundamental role in blood pressure regulation and water-electrolyte
homeostasis [25], [26]. The mere use of medications targeting RAS is by itself proof
of its significance, including AT1R blockers (ARBs), ACE blockers, and renin
inhibitors [25]. Classically, the enzyme renin cleaves the liver-produced
angiotensinogen to generate AngI which is then cleaved to AngII by angiotensin
converting enzyme 1 (ACE1). Angiotensin II (AngII) acts on two different GPCRs
AT1R and AT2R to mediate patho-physiological responses [26]. However, AT1R is
regulating most of these responses induced by AngII [27]. AT1R is widely expressed
in different tissues in the human body, including vascular tissues, adrenal glands,
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adipose tissues, placenta, heart, lungs, and kidneys among others [28]. Ang II through
the binding and activation of AT1R, controls many physiological responses including
vasoconstriction, proinflammatory, fibrotic, oxidative stress, Alzheimer disease, and
insulin resistance among others [27]. On the other hand, AT1R is implicated in many
pathophysiological responses such as renal and cardiovascular diseases, fibrosis,
aging, and cancer [27], [29]–[31]. AngII binding to AT1R induces conformational
changes and activation through Phe8(ANG II)/His256(AT1R) and Tyr4(ANG
II)/Asn111(AT1R), inducing the coupling to the heterotrimeric G proteins including
Gαq, mediating Phospholipase C activations and production of the second messenger
inositol trisphosphate/Ca2+ controlling vasoconstriction, aldosterone release and
water-salt hemostasis [27], [32]. In addition, AT1R signals through Gα12/13, and Gαi
mediating activation of several kinases of serin/threonine, receptor tyrosine kinases,
and non-receptor tyrosine kinases such as G12/13 Rho/Rho kinase, extracellular
signal-regulated kinases (ERK1/2) and mitogen-activated protein kinase (MAPK)
[27], [32] (Figure 4).
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Figure 4: AT1R signaling [33].

1.5 Thrombin and its Receptors
The thrombin system is part of the coagulation cascade with a classical function in the
formation of fibrin clots and coagulation hemostasis. Thrombin mediates its effects
through multiple protease-activated receptors (PARs) belonging to GPCR family.
They are four receptors; PAR1, PAR2, PAR3, and PAR4 [34]. The importance of
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PAR1 immerged as being a common therapeutic modulator for its crucial role in
physiological regulation of vascular tone, platelets activation, and proinflammatory
responses [35], [36]. Also, it contributes to the pathogenesis of multiple diseases such
as atherosclerosis, vascular lesions, inflammation, and cancer [34], [35]. PAR1 is
expressed in various tissues including heart, spleen, lungs, gall bladder, adrenal gland,
brain, and other tissues [37]. It is activated in a unique way, the serine protease
thrombin enzyme cleaves the N-terminus of PAR1 at R41 S42, the cleaved N-termini
acts as a tethered ligand that binds to the ECL2, activating PAR1 downstream signaling
[34]. Other proteolytic cleavages at different sites of PAR1 are mediated through other
proteases such as plasmin, trypsin, factor Xa and VIIa [35]. PAR1 has overlapping
downstream signaling depending on the tissue, cell, cleaving protease, as well as
soluble ligand binding (such as TFLLRN) [34], [35]. PAR1 signals through the
heterotrimeric G-protein including Gαq, Gα12/13, and Gαi, also via the G-proteinindependent pathway controlling diverse biological responses (Figure 5).
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Figure 5: PAR1 signaling [38].

1.6 The Interplay between RAS and Thrombin
Several studies have demonstrated the physiological and pathological interplay
between the Renin Angiotensin System (RAS) and Thrombin system. However, at the
pharmacological level of their respective receptors, this is not well explored yet. Both
the RAS and thrombin systems regulate mutual physiological responses of vascular
development, thrombosis, platelet activation and vascular tone, among others. As well
as pathological responses such as cardiovascular diseases, VSMCs chemotaxis and
proliferation, inflammation, diabetes, and cancer. Antoniak et al. have documented in
their study that, PAR-1 has a role in AngII-mediated pathological cardiac and vascular
remodeling and perivascular fibrosis of the heart and aorta [39]. Also, that PAR1
affects AngII-induced inflammatory cytokines and profibrotic genes in aorta, and these
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effects were attenuated in PAR1 deficient mice [39]. Also, as thrombosis is a major
complication with AngII-induced hypertension, a study by Senchenkova et al.
demonstrated a link between these two complications as AngII promotes
microvascular thrombosis via the help of thrombin [40]. In vivo studies by Steinberg
have documented that activation of PAR1 has two opposing vasoregulatory
mechanisms: endothelial-dependent vasorelaxation and endothelium/vascular smoothmuscle-dependent vasoconstriction responses [41]. Another recent study by Hasan et
al. supported the previous evidences of the physiological interplay between the two
systems, stated that thrombin contributes to atrial endothelial ageing and senescence
via AT1R and ACE upregulation contributing to myocardium remodeling [42]. This
effect was attenuated by ARB in addition, co-targeting both thrombin and angiotensin
is suggested as well for targeting the observed pro-inflammatory, pro-thrombotic, profibrotic and pro-remodeling responses [42]. To add more, Anwar et al.’s study proved
that both Ang II and thrombin significantly dropped down IGFBP-4 protein and
mRNA levels in VSMCs, and may have a crucial role in normal and pathological
vascular growth mediated by Ang II and thrombin via increasing IGF-I availability to
bind its receptor [43]. Therefore, all this evidence together supports the possibility of
the interaction between AngII and thrombin at the level of their receptors.
In regard to this study of the possibility that AT1R and PAR1 to form heterodimers,
Table 1, summaries almost all the reported heterodimers of AT1R as it acts as a
signaling hub and it interacts with many GPCRs as well as Tyrosine kinases.

Table 1: The different AT1R-heterodimers described and characterized in vitro and/or in vivo.
Dimer

Present
In
vitro/vivo

Pharmacological Effects

Physiological Effects

Major Techniques

References

AT1RAT1R

Both

Positive allosteric modulation.

Atherogenesis.

Immunoblotting, IHC,
BRET, & Ligand
dissociation assay.

[44], [45]

AT1RAT2R

Both

AT2R antagonizes AT1R function.

Na+ reabsorption & Ca+2 regulation in renal proximal tubule cells.

Co-IP, Confocal
microscopy, BRET, &
Electrophoretic mobility
shift assay.

[46], [47, p.
3], [48, p. 2],
[49], [50]

AT1RMasR

Both

1. MasR antagonizes AT1R in a ligand independent manner.

1. MAS-knockout mice had enhanced vasoconstriction in the vessels.
Also, had AT1R altered signaling in the amygdala.

Co-IP & BRET

[51]–[54]

Ang II–induced hypersensitivity in preeclampsia.

Co-IP, FRET & BRET

[55]–[59]

NE hypersecretion and sympathetic nerve hyperactivity in vivo.

FRET, BRET, IF, &
Radioligand binding assay.

[60]

healthy pregnant rats showed less dimers compared to preeclamptic
rats. Thus, this dimerization might be inducing preeclampsia.

Co-IP

[61]

BRET

[62]

2. MasR mediates ERK1/2 activation via AT1R.
2. MasR upregulates AT1R through Gq activation of AT1R, but it
decreases AT1R signaling.
AT1RB2R

Both

1. AT1R enhanced signaling.
2. Co-internalization.

AT1Rα2cAR

Both

AT1Rα1dAR

both

AT1Rβ2AR

In vitro

Dual agonist occupancy resulted in unique Gs activation.

AT1R enhances β-arrestin binding to β2AR.
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Table 1: The different AT1R-heterodimers described and characterized in vitro and/or in vivo (continued).
AT1RCB1R

In vitro

1. Potentiation of AT1R signaling & AT1R coupling to multiple
G-proteins.

The heteromer affects Ang II-mediated pathophysiological
profibrogenic effect via AT1R.

Co-IP & BRET

[63], [64]

1. Apelin antagonizes Ang II-induced hypertension and cardiac
fibrosis via inhibiting AT1R signaling.

Co-IP & BRET

[65]–[67]

AT1R-P2YR heteromers increase in vascular smooth muscles due to
the increase in P2YR expression with age. Thus, inducing Ang IImediated hypertension & vascular remodeling in age-dependent
manner.

Co-IP & BRET

[68], [69]

Both GPCRs allosterically modulate each other’s activity.

Potentiates aortic smooth muscles contraction.

Co-IP & BRET

[70]–[72]

AT1R plays dual allosteric modulatory function, one is as a
negative allosteric modulator when it is inactivated & as a positive
allosteric modulator when it is activated & potentiation of cAMP
production.

Regulation of drinking behavior in response to hyperosmotic stress
by:

BRET & FRET

[73]–[76]

2. AT1R induces paracrine transactivation to CB1R.
3. Antagonizing CB1R, inhibits Ang II-mediated mitogenic
signaling and profibrogenic gene expression.
AT1RAPJ

Both

1. APJ allosterically trans-inhibit AT1R.
2. Diminished IP1 production & β-arrestin recruitment.

2. APJ blocks Ang II pathophysiological effect in vascular diseases
through NO production.
3. APJ inhibits the development of Ang II-mediated atherosclerosis.
4. Apelin has hepatoprotective response against hepatic ischemia
reperfusion injury, which is via down regulating hepatic AT1R
expression and increased hepatic apelin level.
AT1RP2Y6

Both

1. Heteromer formation suppresses β-Arrestin recruitment into
AT1R upon Ang II treatment. On the other hand, it enhances Gprotein dependent signaling.
2. UDP (P2Y6 ligand) has no effect on the heteromer.

AT1RFP

In vitro

AT1RSecR

Both

1. Vasopressin release to increasing water intake.
2. Ang II-induced aldosterone secretion through Ca+2 mobilization.
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Table 1: The different AT1R-heterodimers described and characterized in vitro and/or in vivo (continued).
AT1REGFR

Both

AT1R transactivates EGFR.

1. Ang II-mediated pathological remodeling of cardiomyocytes, their
growth & cardiac hypertrophy.

Co-IP & BRET

[77]–[81]

BRET

[82]–[84]

Co-IP & Glutathione-Stransferase pull-down
assays.

[85]–[87]

BRET,
Immunocytochemistry, colocalization & proximity
ligation assay.

[88]

2. AT1R-EGFR crosstalk regulates the development of the renal
collecting system.
AT1RCCR2

Both

Co-treatment with Ang II & CCL2 has a positive allosteric
modulation effect on Gi coupling and β-arrestin recruitment (This
effect was lost with co-antagonizing the two receptors).

Chronic kidney disease. (blocking both AT1R & CCR2 lessen
proteinuria, ischemic brain damage macrophage infiltration,
podocyte loss, & crescentic Glomerulonephritis.
CCR2 deficiency significantly disturbed the formation of Ang IIinduced ascending aortic aneurysms, abdominal aortic aneurysms,
and atherosclerosis.

AT1RD1R

Both

1. Losartan acts as a positive allosteric modulator for

1. Regulation Na+ excretion and blood pressure.

D1R activation. it also enhanced cAMP production by both
GPCRs.

2. Losartan antihypertensive function might be mediated by both
blocking AT1R signaling and through enhancing D1R signaling.

However, D1R antagonist blocked the antihypertensive effect of
Losartan.

3. Region in carboxyl terminus of D1R (residues 397-416) was found
to interact with both AT1R as well as Na+-K+-ATPase.

2. Ang II mediated rapid partial internalization of D1R plus
blocking D1R signaling. Also, D1R ligand mediated rapid partial
internalization of AT1R plus blocking AT1R signaling.
3. Fenoldopam (D1 like ligand) positively modulates D1R's and
negatively AR1R's expression in VSMCs and RPT cells from
normotensive rats. However, it has no effect on D1R of
hypertensive rat cells and still blocks AT1R.
AT1RD2R

Both

1. Cross-antagonism of the two GPCRs.

Cross-antagonism by ARB blocks D2R signaling causing

2. downregulation of AT1R-mediated Ca+2 mobilization cotransfected cells.

enhanced D2R-mediated dopaminergic transmission, which control
the basal ganglia system of motor control.

15

Table 1: The different AT1R-heterodimers described and characterized in vitro and/or in vivo (continued).
AT1RD3

In vitro

1. AT1R down regulates D3R expression in RPT cells.

Co-IP

[89]

2. AT1R-D3R interact in RPT cells, but this interaction is
impaired in SHR (spontaneous hypertensive rats) compared to
WKY.
AT1RD4

Both

D4R receptor down-regulates AT1R expression in WKY RPT
cells through ca+2 channels activation.

Regulating Ang II- induced hypertension.

IF & Immunoblotting.

[90]

AT1RD5

Both

1. Negatively regulate the expression of each other.

Regulating Ang II- induced hypertension.

BRET, Co-localization, &
Immunoblotting.

[91]–[93]

1. Progressive hypertension.

IF & Proximity Ligation
Assay.

[94]

Co-IP, Co-localization

[95]–[98]

Co-IP, IF & FRET

[99], [100]

2. D5R mediates AT1R degradation through ubiquitin-proteasome
pathway.
AT1RμOR

In vivo

1. Deceases Nitric Oxide (NO) production thus elevating blood
pressure.
2. Losartan enhanced the production of NO.

ET1RAT1R

Both

1. Ang II decreases ET1R phosphorylation.

2. Blocking AT1R has improvement effect against this heterodimermediated response.
1. AT1R & ET1R expressed on immune cells enhance chemotaxis
and expression of IL-8 & CCL18 upon production of autoantibodies
from systemic sclerosis patients.
2. These Abs enhance severe obliterative vasculopathy in graft versus
host and systemic sclerosis.
3. AT1R regulates ET1R expression.
4. Ang II-mediated hypertension enhances arterioles thrombosis, and
this response is mediated by AT2R, AT4R, B1R, and ET1R–
mediated signaling.

AT1RPRR

Both

PRR blockage prevents diabetic nephropathy (including the antifibrotic effect) which is caused by ARBs.
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Table 1: The different AT1R-heterodimers described and characterized in vitro and/or in vivo (continued).
AT1RTPαR

In vitro

TPαR upregulates AT1R's function via paracrine transactivation
of the TPαR.

Pathogenesis of Ang II-mediated hypertension and cardiac
hypertrophy.

BRET & Receptor Selection
and Amplification
Technology.

[101], [102]

17

18

Chapter 2: Hypothesis and Objectives
2.1 Hypothesis
This thesis work hypothesized that the previously mentioned physiological and
pathological interplay between RAS and thrombin systems, happens at the level of
their receptors AT1R and PAR1, respectively.

Figure 6: The hypothesis of heterodimerization between AT1R and PAR1.

2.2 Objectives
This study aimed to investigate the physical and functional interaction between AT1R
and PAR1 in vitro. For this, the two GPCRs were co-expressed in human embryonic
kidney (HEK293) cells and bioluminescence resonance energy transfer (BRET) and
immunoblotting assays were used:
1- To investigate the physical interaction between AT1R and PAR1 by
assessment of PAR1-AT1R molecular proximity using Co-IP and BRET

19
Saturation Assay.
2- To investigate the functional interactions between AT1R and PAR1 in terms
of heterodimerization by investigating; Gq protein activation, -arrestin
recruitment, second messenger production (IP1/3), MAP Kinase, and receptor
trafficking/internalization by using Dose response and Kinetics BRET/FRET
based technology as well as Western blot.

Figure 7: Objectives of the study.
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Chapter 3: Materials and Methods
3.1 Chemicals, Reagents, and Plasmid
PAR1was purchased from cDNA Resource Center (Bloomsberg, PA, USA), HAAT1R was kindly provided by Reiter E. (INRA, Nouzilly, France), AT1R-Rluc was a
gift from Laporte, S. (McGill University, Montréal, Canada), yPET-β-arrestin 2 was
kindly provided by Scott, M. (Cochin Institute, Paris, France), Grb2-Rluc, Grb2Venus, PAR1-Rluc, and PAR1-Venus were kindly given by Prof. Pfleger KD. (Harry
Perkins Institute of Medical Research and UWA, Perth, Australia), and Venus-Gαq,
Venus-Kras, and Venus-Rabs that were generously shared by Lambert, N. (Augusta
University, GA, USA). AngII, thrombin, and irbesartan were from Sigma (St Louis,
MO, USA). SCH79797 was from Tocris (Tocris, Ellisville, MO). The IP1 kit was
obtained from Cisbio Bioassays (PerkinElmer, Codelet, France) and the anti-HA tag
antibody (ab9110) was purchased from abcam (abcam, MA, USA). Lipofectamine™
2000 from (Invitrogen) for transfection and Coelenterazine h the luminescent substrate
was purchased from Promega (Promega Corporation, Madison, WI, USA).
3.2 Bacterial Transformation and Plasmid Extraction
The plasmids were received on a paper to be transformed; they were resuspended in
50 µl nuclease free water (NF) for ~ 15 minutes. NEB 5-alpha Competent E. coli (High
Efficiency) from NEW ENGLAND BioLabs, was used for transformation according
to manufactural instructions. First, the plasmid DNA and cell mixture were flicked
several times for mixing. Then, the mixture was incubated for 10 minutes on ice,
followed by heat shock at 42ºC for 30 seconds, again incubation for 5 minutes on ice
took place. Next, 500 µl of room temperature SOC Outgrowth Medium was added to
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the DNA-cells mixture and incubated for one hour at 37ºC on a shaker (400 rpm). After
that, centrifugation at 5000 rpm/5 minutes was carried out and the supernatant was
discarded. Then, the Pellet was resuspended in 50-100 µl SOC medium, and streaked
on LB Agar plates containing the selective antibiotic (Ampicillin or Kanamycin) with
overnight incubation at 37ºC. To prepare liquid culture, a single colony from the plate
was immersed with 200 mL LB medium containing the selective antibiotic for
overnight incubation at 37ºC in the shaking incubator. Next day, the transformed
bacteria were pelleted by centrifuging the liquid culture at high speed 6000 rpm/15
minutes.
Plasmids were extracted from the bacterial pellets using the Qiagen® Plasmid Maxi
kit as per manufacturer’s guidance. Finally, Extracted DNA was resuspended in NF
and plasmid concentrations were measured using the NanoDrop 2000 (Thermo
Scientific) while Plasmid integrity was assessed by running agarose gel
electrophoresis.
3.3 Cell Culture and Transfection
Human embryonic kidney (HEK293) and human epithelial colorectal adenocarcinoma
(HT-29) cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco) supplied with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml
streptomycin (Sigma-Aldrich) at 37°C in 5% CO2.
Transient transfection using HEK293 cells were carried out in 96-well plates with
Lipofectamine 2000 by using one third of the 75T 100% confluent flask (~100,000
cells/ well). Briefly, the 96-plates were coated with Poly-L-Lysine for 30 minutes at
37ºC, then washed with PBS 3 times. Meanwhile, the transfection mixtures were
prepared: 1) plasmid-mix (plasmid mixed with 25 µL Opti-MEM™ media from Gibco
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per well), 2) Lipofectamine-mix (0.5 µL of Lipofectamine 2000 mixed with 25 µL
Opti-MEM™ ) each was incubated for 5 minutes at room temperature. Then, the two
mixes were combined and incubated for another 20 minutes. Finally, 50 µL of this
transfection mix plus 150 µL cells per well were seeded in the 96-well plate. Next day,
cells were starved with DMEM-Serum free medium. And after 48 hours transfection,
BRET experiments were conducted using the Tristar 2 multilabel plate reader
(Berthold, Germany) that allows the sequential integration of light emission detected
with two filter settings (480 ± 20 nm and 540 ± 25 nm).
3.4 Transfection Efficacy
Expression of Rluc-tagged proteins was assessed by the addition Coelenterazine h
luciferase substrate to measure light emission at 480 nm using the Tristar 2 plate
reader. While for the acceptor-tagged proteins (yPET or Venus), was assessed by
visual checking using fluorescent microscopy and by reading light emission at 540 nm
using the Tristar 2 plate reader.
3.5 BRET and FRET based Assays
Bioluminescence resonance energy transfer (BRET) is a quantitative technology used
to study protein-protein interaction in living cells and in real time. It is based on
resonance energy transfer from a lumenscient energy donor (luciferase-tag) into a
fourscent energy acceptor (fluorescent tag) fusions to the ptoteins to be studied. If the
two tagged proteins are in close proximity within 10 nm (100 Å), uppon addition of
luceiferase substrate, the luceferase will emit light at 480 nm which is within the
excitation spectrum of the acceptor, thus allowing emession of the acceptor at 530 nm.
The ratio of energy from acceptor’s emission relative to donor’s emission is termed
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the BRET signal, or BRET ratio [103] (Figure 8). The fluorescence resonance energy
transfer (FRET) differs from BRET with only having a fluorescent donor instead of a
luminescent donor. In this study various BRET and FRET-based assays were used to
investigate the physical and functional interaction between AT1R and PAR1,
including saturation assay, dose response, real-time kinetics, and IP1 measurement.

Figure 8: BRET technology.

3.5.1 BRET Saturation Assay
BRET saturation assay was used to validate the specificity on the interaction between
AT1R and PAR1. Cells co-expressing a constant amount of AT1R-Rluc (25 ng)
without or with increasing amount of either PAR1-Venus or Grb2-Venus as a negative
control (10, 20, 40, 60, 80, 100, 120, 140, 160, 175 ng) were first seeded in 96-well
white (for BRET and luminescence measurements) and black (for fluorescence
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measurements) plates, washed with 50 μl/well of PBS, and resuspended in 40 μl of
PBS. Then, 10 μl of coelenterazine h (2.5 µM) were added and BRET signals were
measured. In parallel, the specific luminescence of AT1R-Rluc was measured using a
485 nm emission filter, and the specific fluorescence of PAR1-Venus and Grb2-Venus
was quantified using the 485 nm excitation filter and 540 nm emission filter on the
Tristar 2 multilabel plate reader. Then, net BRET signals were correlated and plotted
over the fluorescence/luminescence ratios (Venus/Rluc ratios).
3.5.2 BRET Dose Response
Dose-response BRET experiments were conducted to assess AngII- as well as
thrombin -induced AT1R/Gaq coupling and AT1R/β-arrestin 2 recruitment by
transfected HEK293 cells coexpressing AT1R-Rluc (25 ng) with either Venus-Gaq or
yPET-β-arrestin 2 (25 ng) in the absence or presence of PAR1 (50 ng), were seeded
into 96-well plates. 48 hours post-transfection, cells were starved with serum free
medium for at least 3 hours before conducting BRET experiments. Then, cells were
washed with 50 µL PBS and 50 µL as total reaction volume per well was used. For
AngII dose response assay, 20 µL of the different doses of AngII with 20 µL of PBS
or saturating dose of thrombin (1 U/mL). While for thrombin dose response assay, 20
µL of the different doses of thrombin with 20 µL of PBS or sub-saturating dose of
AngII (10 nM). Each followed by incubation for 30 minutes at 37ºC. Then, 10 μl of
coelenterazine h (Promega) was added in a final concentration of 2.5 µM and BRET
measurements were carried out using the Tristar 2 multilabel plate reader (Berthold,
Germany) that allows the sequential integration of light emission detected with two
filter settings (480 ± 20 nm and 540 ± 25 nm).
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Figure 9: Assessment of G-protein activation and β-arrestin recruitment by AngII and
thrombin.
3.5.3 Real-Time Kinetics BRET
Real-time kinetics experiments were conducted for further investigation of AngII- as
well as thrombin -induced AT1R/Gaq coupling and AT1R/β-arrestin 2 recruitment.
Transfected HEK293 cells co-expressing AT1R-Rluc (50 ng) with either Venus-Gaq
or yPET-β-arrestin 2 (50 ng) in the absence or presence of PAR1 (50 ng) were seeded
into 96-well plates. 48 hours post-transfection, cells were starved with serum free
medium for at least 3 hours before conducting BRET experiments. Two different
kinetics protocol were used. Cells were first washed with 50 µl/well of PBS and
resuspended in 40 µl/well of PBS containing coelenterazine h (2.5 µM), and BRET
signals were measured in real time for ∼5 min to determine the baseline. In the first
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direct protocol, after the baseline, 10 µl/well of PBS containing or not, either 10 nM
of AngII, thrombin 1 U/mL, or both, was added, and BRET measurements were carried
out for 35 minutes. While in the second sequential protocol, after the baseline, BRET
signals were measured in real time upon two sequential treatments (T1 then T2). This
consists of 10 µl/well of PBS containing or not 10 nM of AngII (T1) for 15 minutes of
BRET measurements followed by 10 µl/well of PBS containing or not 1 U/mL of
thrombin (T2) for ~45 minutes of BRET measurements.
3.5.4 BRET Titration
BRET titration for AT1R-Rluc/Venus-Gq coupling was conducted to assess the effect
of different expression levels of plasmids on AT1R-Gq coupling. For this, HEK293
cells were cotransfected with 25 ng Venus-Gq with different amounts of AT1R-Rluc
(10, 25, or 50 ng) in the absence or presence of different amounts of PAR1 (5, 10, 25,
50, or 100 ng), and seeded into 96-well plates. 48 hours post-transfection, cells were
starved with serum free media for at least 3 hours before conducting BRET
experiments. Then, cells were washed with 50 µL PBS and 50 µL as total reaction
volume per well was used. Stimulation with either 10 nM AngII, 1 U/ml thrombin, or
both for 30 min at 37°C and addition of 10 µL coelenterazine h (2.5 µM) before BRET
signals were measured in live cells.
3.5.5 BRET with Antagonists
HEK293 cells transiently co-expressing AT1R-Rluc (25 ng) with either Venus-Gq or
yPET-β-arrestin 2 (25 ng) in the absence or presence of PAR1 (50 ng) were seeded
into 96-well plates. 48 hours post-transfection, cells were starved with serum free
medium for at least 3 hours before conducting BRET experiments. Then, cells were
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washed with 50 µL PBS, First, cells were pretreated or not (control) with 30 µL
antagonists; SCH79797 (100 mM) or irbesartan (10 µM) and incubated for 15 minutes
at 37°C. Then, 10 µL ligands treatment of either 10 nM AngII, 1 U/mL thrombin, or
both were added followed by further incubation for 30 min at 37°C and addition of 10
µL coelenterazine h (2.5 µM) before BRET signals were measured in live cells
3.5.6 IP1 FRET
IP measurement was conducted using the HTFR assay IP-One Tb kit (Cisbio
Bioassays, France) according to the manufactural instructions. It is a fluoresce
competitive immunoassay based on the principle of FRET that uses selective
monoclonal anti-IP1. For this HEK293 cells were transfected to express either AT1RRluc, PAR1, or both, and HT-29 cells (with endogenous AT1R and PAR1).
Measurement of IP1 accumulation was performed For this, cells were first pre-treated
or not (Control) with 30 µl of SCH79797 (100 μM) or irbesartan (10 μM) prepared in
the stimulation buffer 1X that contains LiCl2 to inhibit IP1 degradation, and incubated
for 15 min at 37°C. Then, 10 μl of either AngII (10 nM), thrombin (1 U/ml), or both
were added followed by further incubation for 30 min at 37°C. For the dose-response
experiments, 40 µl of increasing doses of AngII or thrombin in the stimulation buffer
1X were used. The cells were then lysed by adding the supplied assay reagents, and
the assay was incubated for 1 h at room temperature. Fluorescence emission was
measured at 620 nm and 665 nm, 50 µs after excitation at 340 nm using the Tristar 2
multilabel plate reader (Berthold, Germany).
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3.5.7 Trafficking and Internalization
Internalization and endosomal trafficking of AT1R assessed by BRET assays.
HEK293 cells transiently coexpressing AT1R-Rluc (25 ng) with either Venus-Kras,
Venus-Rab5, or Venus-Rab7 (25 ng) in the absence or presence of PAR1 (50 ng) were
used. For BRET measurements, cells were washed with 50 µL PBS, then stimulated
or not with either 10 nM of AngII, 1 U/ml of thrombin, or both, for 30 min at 37°C,
and addition 10 µL of coelenterazine h (2.5 µM) before BRET signals were measured
in live cells.
3.6 Co-immunoprecipitation
HEK293 cells coexpressing or not HA-AT1R with either AT1R-Rluc, PAR1-Rluc, or
Grb2-Rluc were used for immunoprecipitation with the anti-HA antibody followed by
the
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luciferase
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luminescence
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carried

directly
out

on

the

using
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immunoprecipitation (Protein A) assay kit (Roche). Briefly, cells were solubilized in
lysis buffer. An equal amount of each protein lysate of Rluc-tagged proteins indicated
by their similar luminescence signal (2500000 a.u.) measured at 485 nm was incubated
overnight with protein A agarose only for pre-clearing. Precleared lysate (1 ml) was
then incubated with the anti-tag HA antibody (3 µg/ml) for 2 h at 4°C, followed by
incubation with 25 µl of protein A agarose beads overnight at 4°C. Beads were washed
as per the manufacturer’s instructions and the final immunoprecipitates were then
resuspended in 50 µl of PBS in 96-well white plate followed by the addition of 10 μl
of coelenterazine h (5 µM) as Rluc substrate. The amount of Rluc luminescence in
each complex was then measured using a 485 nm emission filter on the Tristar 2 plate
reader.
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3.7 SDS-PAGE and Western Blot
HT-29 cells (endogenously express AT1R and PAR) along with transfected HEK293
cells with 0.5 µg of either AT1R-Rluc, PAR1-Venus, or both together and seeded onto
6-well plates at a density of 106 cells per well. Cells were starved overnight with
DMEM-serum free media. Then, cells were washed with PBS and stimulated or not
with either 1 µM, or 10 nM AngII, 1, or 0.1 U/ml thrombin, or both for 5 minutes or
30 minutes at 37ºC. After treatment, the cells were washed in cold PBS and lysed with
200 μL/well of ice-cold RIPA lysis buffer (Pierce) supplemented with
phenylmethylsulfonyl fluoride (PMSF) (Roche) and protease inhibitors (SigmaAldrich) and incubated for 90 minutes at 4°C. Cell lysates were then scraped and
collected, followed by centrifugation at 15000 g for 15 minutes at 4°C to remove cell
debris. Then, proteins were quantified using BCA Protein Assay Kit (Thermo Fisher
Scientific). After that for 10% SDS-PAGE (at 225 V for ~ 1 hour), equal amounts of
each protein from each cell lysates sample was mixed with Laemmli buffer (Bio-rad)
containing 8% β-mercaptoethanol and heated for 5 minutes at 95°C, and transferred to
polyvinylidene fluoride (PVDF) (Bio-Rad) membranes by conventional wet-transfer
technique (100 V for 90 minutes). The membranes were incubated for blocking at
room temperature for 1 hour in 5% skimmed milk prepared in PBS (Gibco) containing
0.1% Tween 20 (Bio-Rad) (PBST) for 1 hour. And the membranes were incubated
overnight at 4°C with primary anti-ERK antibodies; primary mouse monoclonal anti–
pERK1/2 (Cell Signaling) (1:2,000 dilution in TBST containing 5% skimmed milk)
for the phosphorylated proteins or primary rabbit polyclonal anti-ERK1/2 (1:1,000
dilution in TBST containing 5% bovine serum albumin) for total proteins. Membranes
were incubated for 45 minutes with secondary IgG anti-rabbit or anti-mouse
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conjugated to horseradish peroxidase (HRP) as per manufactural instructions.
Followed by detection of the immunoreactive bands by chemiluminescent substrate
(Thermo Fisher Scientific), and HRP was detected by chemiluminescence using the
LiCOR C-DiGit Blot Scanner.
3.8 Data Presentation and Statistical Analysis
The BRET values were achieved by the ratio of energy emitted at 540 nm/ energy
emitted at 480 nm. Then this BRET ratio was converted into “ligand-induced BRET”
signals by subtracting the ratio obtained from vehicle-treated cells from the same ratio
obtained from AngII/thrombin-treated cells. Then, the % of responses in the different
BRET and IP1 assays were obtained by taking as 100% the maximal AngII/thrombininduced responses in the control condition. All kinetic and the sigmoidal dose-response
curves were fitted to appropriate nonlinear regression equations using GraphPad Prism
software (San Diego, CA, USA). Statistical analyses were performed with two-way
ANOVA and multiple comparisons test to determine statistical significance between
the different conditions relative. ****p-value < 0.0001, ***p-value < 0.001, **p-value
< 0.01, * p-value < 0.05, and ns p-value > 0.05.
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Chapter 4: Results
4.1 Fluorescence Microscopy
Transfection validation was performed as previously mentioned by reading the
expression of Rluc- and Venus- tagged proteins at 480 nm and 540 nm, respectively
using the Tristar 2 plate reader. In addition, fluorescent microscopy visualization was
performed. As shown in Figure 10, fluorescent tagged proteins were expressed in the
cytosol of transfected HEK293 cells, Venus-Gq in Figure 10A and yPET-Arrestin in
Figure 10B. Therefore, validating the transfection and expression of these proteins 48
hours post-transfection.

Figure 10: Fluorescence microscopy confirmed the transfection. Visualization of
transfected HEK293 cells with AT1R-Rluc/Venus-Gq (A) and AT1R-Rluc/yPETArrestin 2 (B) by fluorescence microscope, validating the cytosolic expression of the
fluorescent tagged proteins Venus Gq (A) and yPET-Arrestin (B).
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4.2 The Physical Interaction between AT1R and PAR1
As mentioned previously, the aim of this study is first to check the physical interaction
between AT1R and PAR1 by assessing the molecular proximity between them. For
this, BRET saturation assay was performed followed by CO-IP to confirm this physical
interaction by forming AT1R-PAR1 heterodimer.
4.2.1 BRET Saturation
BRET saturation assay was used to prove the specificity of the BRET signal between
AT1R-Rluc and PAR1-Venus. A fixed amount of the donor AT1R-Rluc (25 ng) was
co-expressed with or without different amounts of the acceptors either PAR1-Venus
or Venus-Grb2 (the adaptor protein as negative control). Theoretically, the BRET
signals should increase with the increased amount of the acceptor until reaching the
stage of saturation where all the donors were consumed, and nothing remained to
excite the left acceptors. Then, the net BRET ratio is blotted over the acceptor/donor
ratio. As shown in Figure 11 A, an increase in BRET signal between AT1R-Rluc and
Venus PAR1 was achieved until reaching the saturation stage and it is demonstrated
in a hyperbolic (blue curve). However, a linear nonspecific BRET signals were
obtained from AT1R-Rluc and Venus-Grb2 interaction (red curve). Thus, confirming
the specific molecular proximity between AT1R and PAR1.
4.2.2

Co-immunoprecipitation

(CO-IP)

Confirmed

AT1R-PAR1

Heterodimerization in Vitro
Then, further confirmation of this physical interaction was done by CO-IP experiment.
For this, the ability of AT1R to heterodimerize with PAR1 was assessed by
transfecting HEK293 to express HA-AT1R with or without either PAR1-Rluc, AT1R-
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Rluc as a positive control for HA-AT1R/AT1R-Rluc homodimers, or Grb2-Rluc as a
negative control, were used. The HA-AT1R was immunoprecipitated using the antiHA antibody, followed by the Rluc luminescence measurement of the PAR1-Rluc coimmunoprecipitated with HA-AT1R. As shown in Figure 11 B, for a similar input of
Rluc tagged proteins used from all the samples a strong luminescence signal was
measured in the immunoprecipitate obtained from HA-AT1R/AT1R-Rluc expressing
cells demonstrating their physical interaction and homodimerization as previously
reported and validating the assay [44], [104]. Moreover, a weaker but significant Rluc
signal was also measured in the immunoprecipitate obtained from HA-AT1R/PAR1Rluc expressing cells (Figure 11 B). Such a signal was observed neither when PAR1Rluc was expressed alone without HA-AT1R nor in the immunoprecipitate obtained
from HA-AT1R/Grb2-Rluc expressing cells indicating the specificity of the coimmunoprecipitation (Figure 11B). These results indicate that AT1R receptors
selectively dimerize with PAR1, but not with Grb2. Together, these data support the
presence of a physical interaction between AT1R and PAR1 when co-expressed in
HEK293 and the formation of AT1R-PAR1 heterodimer in vitro.
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Figure 11: The physical interaction between AT1R and PAR1 studied by BRET
saturation in living cells and co-immunoprecipitation: A) BRET saturation assay was
used to assess the specificity and molecular proximity between AT1R and PAR1 by
using HEK293 cells transfected with constant amount of AT1R-Rluc donor with or
without either the acceptor Venus-PAR1 or Venus Grb2. Then, the net BRET values
were blotted over the Venus/Rluc ratios. B) HEK293 cells transiently co-expressing
HA-AT1R without or with either AT1R-Rluc, PAR1-Rluc, or Grb2-Rluc were used
for coimmunoprecipitation using the anti-tag HA antibody. For this, an equal Rluc
input was used and the final immunoprecipitates were then used for the quantification
of Rluc luminescence of the different Rluc-tagged proteins coimmunoprecipitated or
not with HA-AT1R (co-immunoprecipitated Rluc). The BRET saturation data are
means ± SEM of three to four independent experiments performed in triplicate. The
co-immunoprecipitation data are means ± SEM of three independent measurements.
****p-value < 0.0001 and ns p-value > 0.05.
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4.3 The Functional Interaction between AT1R and PAR1
After assessing the physical interaction between AT1R and PAR1, the functional
consequences of AT1R-PAR1 heterodimerization has been examined. For this, various
biophysical and biochemical techniques were used. BRET and FRET based assays
were used to examine G protein coupling to the heterodimer, β-arrestin 2 recruitment,
second messengers production, heterodimer’s trafficking and internalization, whereas
SDS-PAGE and western blot were used to assess the dimerization effects on the
phosphorylation of the key kinases such as the MAP kinases/ERK pathway.
4.3.1 BRET Dose Response Confirmed the Functional Interaction between AngII
and Thrombin through AT1R-PAR1 Heterodimer
The effect of thrombin treatment and the transient overexpression of PAR1on the
functional coupling of AT1R with the heterotrimeric Gq protein, and the recruitment
β-arrestin 2 was examined. For this, BRET technology using live HEK293 cells coexpressing AT1R-Rluc (as BRET donor) and either Venus-Gq or yPET-β-arrestin 2
(as BRET acceptors) in the absence or presence of PAR1 overexpression and
stimulated without or with either AngII, thrombin, or co-stimulated.
Starting with dose-response analysis to assess the specificity of the ligands, AngII and
thrombin for binding their respective receptors, AT1R and PAR1 (Figure 12). HEK293
cells expressing either AT1R-Rluce or PAR1-Rluc with Venus-Gq were treated with
increased doses of either AngII (Figure 12 A) or thrombin (Figure 12 B). A dose
response stimulation was obtained, showing increase in the BRET signals with the
increased doses of ligands until reaching saturation. AngII dose response showed a
dose dependent BRET signals (Figure 12 A) between AT1R-Rluc/Venus-Gq
transfection, but not between PAR1-Rluc/Venus-Gq. Similarly, the thrombin dose
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response was between PAR1-Rluc/Venus-Gq, but not AT1R-Rluc/Venus-Gq.
Together, these findings confirm the specificity of the receptors to their ligands and
their functional activity for Gq coupling in a dose-dependent manner. Moreover, this
analysis guided us to determine AngII EC50 (10 nM) as well as the Emax of thrombin
(1 U/ml) concentrations to be used in all the protocols in this study. Then, AngII dose
response analysis was conducted with increasing AngII doses without or with 1 U/ml
thrombin in cells expressing AT1R-Rluc with either Venus-Gq (Figure 12 C, D) or
yPET-Arrestin 2 (Figure 12 E, F) in the presence (Figure 12 D, F) or absence (Figure
12 C, E) of PAR1 overexpression. Again, here a dose-dependent BRET increase was
achieved between the donor and acceptors as was shown in Figure 12 A and B. In the
absence of PAR1 overexpression (Figure 12 C, E), when AngII doses were combined
with 1 U/ml thrombin stimulation, did not induce a BRET increase, but showed a
significant lift-shift of the dose response curves of AngII between AT1R-Rluc/VenusGq (Figure 12 C) and AT1R-Rluc/yPET-Arrestin 2 (Figure 12 E) (p-value < 0.0001 or
p-value < 0.001). These data revealed a positive allosteric modulation by the 1 U/ml
thrombin on AT1R, as the Gq Log EC50 values were -7.99 ± 0.08 and -8.82 ± 0.1 (pvalue <0.0001, n=4) and for β-arrestin 2 the Log EC50 values were -8.32 ± 0.10 and 9.44 ± 0.11 (p-value <0.0001, n=3) in the absence and presence of thrombin,
respectively. This positive modulation of AT1R by thrombin might be due to the
endogenously expressed PARs in HEK293 cells that has been reported previously
[105], [106]. Whereas in the presence of PAR1 overexpression, the co-stimulation with
1 U/ml thrombin combined with AngII doses induced a significant increase in the
BRET signals of~75% with AT1R-Rluc/Venus-Gq/PARA (Figure 12 D) and ~25%
withAT1R-Rluc/yPET-Arreestin 2/PARA (Figure 12 F) cells (P-value <0.0001).
Excitingly, these data clearly show the positive allosteric effect of thrombin through
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its receptor PAR1 to transactivating AT1R and thus, confirming the functional
consequences of AT1R-PAR1 hetrodimerization mediating Gq coupling and βArrestin 2 recruitment in an activated PAR1-dependent manner. Moreover, thrombin
dose response was done as shown in Figure 13, for further confirmation of the
functional interaction of AT1R-PAR1 heterodimer and the transactivation of AT1R by
activated PAR1. HEK293 cells expressing AT1R-Rluc/Venus-Gq/-+PAR1 (Figure 13
A, B) or AT1R-Rluc/yPET-Arrestin 2/-+PAR1 (Figure 13 C, D) were stimulated with
increased concentrations of thrombin doses in the presence or absence of 10 nM AngII.
As expected, in the absence of PAR1 and 10 nM AngII, no thrombin-induced BRET
signal was obtained between AT1R-Rluc/Venus-Gq (Figure 13 A) or AT1RRluc/yPET-Arrestin 2 (Figure 13 C). Again, confirming the specificity of thrombin
ligand toward its receptor PAR1 but not AT1R. However, in the absence of PAR1 and
in the presence of 10 nM AngII combined with the increased doses of thrombin, a
marked dose-dependent BRET increase was observed between AT1R-Rluc/VenusGq (Figure 13 A) as well as between AT1R-Rluc/yPET-Arrestin 2 (Figure 13 C) with
Emax values of 238 to 283 ± 39% and 304 ± 57% (p-value <0.0001, n=4), respectively
compared to 100% of AngII single stimulation. This demonstrated the positive
allosteric effect of AngII at EC50 concentration on the thrombin dose-reponse curve.
While in the presence of PAR1 overexpression (Figure 13 B, D), thrombin alone
induced a weak increase in the BRET dose response curve between AT1RRluc/Venus-Gq/PAR1 (Emax = 211 ± 34%, p-value <0.0001, n=4) in Figure 13 B and
AT1R-Rluc/yPET-Arrestin/PAR1 2 (Emax = 102 ± 25%, p-value <0.0001, n=3).
However, when thrombin doses are combined with 10 nM AngII, stronger increase in
the dose-dependent BRET signals was shown in cells expressing AT1R-Rluc/VenusGq (Figure 13 B) and AT1R-Rluc/yPET-Arrestin 2 (Figure 13 D), with maximum
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BRET responses of (Emax = 342 ± 33%, p-value <0.0001, n=4) and (Emax = 299 ± 43%,
p-value <0.0001, n=3), respectively compared to 100% of AngII single stimulation.
Together, these findings are consistent with the ones in Figure 12, confirming the
functional allosteric interaction between AngII and thrombin at the level of their
respective receptors heterodimerization to couple Gq and recruit β-arrestin 2, also
these data further confirm the specificity of each ligand with its cognate receptor.
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Figure 12: AngII dose response analysis to assess AngII-induced AT1R-Gq/Arrestin
functional interactions via transactivation. First, the specificity of AT1R and PAR1
towards their ligands was assessed by using HEK293 cells co-expressing either AT1RRluc/Venus-Gq (A) or PAR1-Rluc/Venus-Gq (B). Then, the functional consequences
of AT1R-PAR1 heterodimerization was assessed by dose response analysis using
HEK293 cells expressing AT1R-Rluc with either Venus-Gq (C, D) or yPET-Arrestin
2 (E, F) in the presence (D, F) or absence (C, E) of PAR1 overexpression were treated
without or with increased concentration of thrombin doses combined (blue curves) or
not (black curves) with 10 nM AngII for 30 minutes at 37ºC. BRET signals were
measured in live cells. Data are means ± SEM of three to four independent experiments
performed in triplicate. The statistical analysis indicates the significance relative to the
control curve (the absence of thrombin). ****p-value < 0.0001, ***p-value < 0.001.
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Figure 13: Thrombin dose response analysis to assess thrombin-induced AT1RGq/Arrestin functional interactions via transactivation. HEK293 cells expressing
AT1R-Rluc with either Venus-Gq or yPET-Arrestin 2 in the presence (B, D) or
absence (A, C) of PAR1 overexpression were treated without or with increased
concentration of thrombin doses combined (blue curves) or not (black curves) with 10
nM AngII for 30 minutes at 37ºC. BRET signals were measured in live cells. Data are
means ± SEM of three to four independent experiments performed in triplicate. The
statistical analysis indicates the significance relative to the condition in the absence of
thrombin for both curves, the control, and the ones in the presence of 10 nM of AngII.
****p-value < 0.0001, ***p-value < 0.001, **p-value < 0.01, *p-value < 0.05.

41
4.3.2 Real-Time Kinetics Confirmed the Ability of AT1R-PAR1 Heterodimer to
Couple Gq and Recruit β-arrestin 2 in a Time Dependent manner
Then, real-time kinetics was performed for further confirmation of the functional
consequences of the dimerization between AT1R-PAR1, via conducting two different
kinetics protocols, direct (Figure 14) and sequential kinetics (Figure 15) as previously
were described. HEK293 cells expressing AT1R-Rluc with either Venus Gq or yPETArrestin 2, in the presence or absence of PAR1 overexpression were used. First, the
basal activity was determined by reading for ~5 minutes without stimulation. Then for
the direct kinetics (Figure 14), reding the baseline was followed or not by the direct
addition of either 10 nM AngII, 1 U/ml thrombin, or their combination for ~35minutes
reading. As demonstrated in (Figure 14 A, C), in the absence of PAR1 overexpression,
the addition of the single treatment of 10 nM AngII, induced BRET signal between
AT1R-Rluc and either Venus-Gq (Figure 14 A) or yPET-Arrestin 2 (Figure 14 C), was
observed up to ~35 minutes. This effect was not observed with 1 U/ml thrombin
treatment alone. Interestingly, the co-stimulation showed a marked increase in the
BRET signal ~200% with Gq and ~220% with β-arrestin 2 compared to 100% single
AngII stimulation (P-value <0.0001). Again, this sharp increase might be due to the
endogenous expression of PARs in HEK293 cells. Whereas in the presence of PAR1
overexpression (Figure 14 B, D), the single treatment of 10 nM AngII induced ~220%
increase in the BRET signal for Gq coupling (Figure 14 B, red curve) and ~246% for
β-arrestin 2 recruitment (Figure 14 D, red curve). Also, with the 1 U/ml thrombin, but
in a less extent with β-arrestin (Figure 14 D, blue curve). And excitingly, with the costimulation, more increase in BRET signals between AT1R-Rluc and either Venus-Gq
(Figure 14 B, green curve) or yPET-Arrestin 2 (Figure 14 D, green curve) was
observed ~250% (P-value <0.0001). These findings further confirm the functional
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consequences of AT1R-PAR1 heterodimerization and its ability to couple to Gq and
recruit β-arrestin in time and dose dependent manner.
Then a sequential real-time kinetics was performed (Figure 15), after measuring the
baseline level, cells were treated without (vehicle) or with 10 nM AngII (treatment 1
or T1) for ~15 minutes, followed by treating cells or not (vehicle) with 1 U/ml
thrombin (Treatment 2 or T2) for ~45 minutes. So, the ligand treatments were added
sequentially to see the effect before and after their single and combined stimulation.
This assay demonstrated consistent results with the dose response and the direct
kinetics analysis, the 10 nM AngII induced increase in the BRET signal between
AT1R-Rluc and both Venus-Gq (Figure 15 A, blue curves) and yPET-Arrestin 2
(Figure 15 C, blue curves). Also, the addition of T2 (1 U/ml thrombin) followed by
vehicle, did not induce a BRET signal between them (Figure A, C, red curves).
However, T1 addition followed by T2 combination, increased the BRET signal (by
137% with Gq and 125% with β-arrestin 2). Together, these results show that 10 nM
AngII was able to induce the coupling of AT1R to Gq as well as to recruit β-arrestin
2, but not the 1 U/ml thrombin. In addition to this, the co-stimulation enhanced this
functional activity with the possibility of the presence of other PARs as previously
explained. On the other hand, when cells are overexpressing PAR1 with AT1R-Rluc
and either Venus-Gq (Figure 15 B) or yPET-Arrestin 2 (Figure 15 D). Here, both T1
(blue curves) and T2 (red curves) when combined with vehicle induced BRET signal
increase. But for T2, it showed a weaker response with β-arrestin (Figure 15 D)
compared to Gq (Figure 15 B). Attractively, the addition of T1 followed by T2,
markedly increased the BRET signal (by ~185% with Gq and 179% with β-arrestin 2).
All these data are consistent with the all the previous results and confirming Gq
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coupling and β-arrestin 2 recruitment to the AT1R-PAR1 heterodimer formation with
the co-stimulation by 10 nM AngII with 1 U/ml thrombin.

Figure 14: Real-time kinetics (Direct protocol) confirmed the functional interaction of
AT1R-PAR1 heterodimerization by BRET. HEK293 expressing either AT1RRluc/Venus-Gq (A, B) or AT1R-Rluc/yPET-Arrestin 2 (C, D), with (B, D) or without
(A, C) PAR1 overexpression were used for real-time BRET kinetic analysis as
described in methods. First, the baseline level was determined with basal reading for
~5 min, followed by the direct ligand treatments for ~35 min reading in real-time.
BRET signals were in real-time and live cells for 35 min. Data are means ± SEM of
10–11 independent experiments performed in single-point measurements. The
statistical analysis indicates the significance relative to the kinetic curves in the
presence of 10 nM of AngII. ****p-value < 0.0001.
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Figure 15: Real-time kinetics (Sequential protocol) confirmed the functional
interaction of AT1R-PAR1 heterodimerization by BRET. HEK293 expressing either
AT1R-Rluc/Venus-Gq (A, B) or AT1R-Rluc/yPET-Arrestin 2 (C, D), with (B, D) or
without (A, C) PAR1 overexpression were used for real-time BRET kinetic analysis
as described in methods. First, the baseline level was determined with basal reading
for ~5 min, followed by T1 (10 nM AngII) or not (vehicle) for ~15 min, and finally T2
(1 U/ml thrombin) with ~45 min reading in real-time. BRET signals were measured in
real-time and live cells for 60 min. Data are means ± SEM of eight to nine independent
experiments performed in single-point measurements. The statistical analysis indicates
the significance relative to the baseline as well as to the kinetic curves in the presence
of 10 nM of AngII. ****p-value < 0.0001, ***p-value < 0.001, **p-value < 0.01, *pvalue < 0.05.
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4.3.3 BRET Titration Assay Demonstrated that AT1R-PAR1 Functional
Consequences Depend on the Receptor Expression Level
Then, BRET titration was performed to check if AT1R-PAR1 heterodimerization is
affected by the receptor expression level. For this, HEK293 cells co-expressing VenusGq with three different amounts of AT1R-Rluc 10, 25, or 50 ng (Figure 16 A, B, and
C, respectively) and with or without PAR1 (0, 5, 10, 25, 50, 100 ng) were stimulated
without or with 10 nM AngII, 1 U/ml, or their combination. Indeed, in the absence of
PAR1 expression, a BRET induced signal between AT1R-Rluc and Venus-Gq was
obtained with 10 nM AngII but not with 1 U/ml thrombin and without any significant
potentiation with the co-stimulation. Moreover, the 25 ng AT1R-Rluc (Figure 16 B)
and 50 ng (Figure 16 C) showed the prettiest response compared to 10 ng (Figure 16
A). Whereas with PAR1 expression, even with the lowest expression amount (5 ng),
the positive functional BRET response between AT1R-PAR1 heterodimer and Gq was
observed. And 1 U/ml thrombin as well as the co-treatment induced a significant
increase in BRET signals with the increased PAR1 levels in the three different figures.
Showing that thrombin through its receptor PAR1 positively modulates AT1R and the
thrombin-induced AT1R transactivation responses were observed in receptor
expression-dependent manner until reaching the saturation level with 25 ng of PAR1.
Whereas 50 ng showed the highest BRET increase (340% with 1 U/ml thrombin and
478% with co-treatment) compared to 25 ng PAR1 (294% with 1 U/ml thrombin and
446% with co-treatment) (P-value < 0.0001), indicating the specificity of the BRET
signals between AT1R-Rluc and Venus-Gq in PAR1’s presence. So, according to these
findings, the BRET experiments were conducted following this expression level of 25
ng AT1R-Rluc with 50 ng PAR1. Moreover, this analysis demonstrated that AT1RPAR1 functional heterodimerization occurs even at very low expression levels of the
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receptors. In addition, transactivation of AT1R by activated PAR1 occurs in a receptor
expression-dependent manner until reaching a saturation, reflecting the specificity of
the BRET signals of Gq coupling to the heterodimer.

47

Figure 16: BRET titration analysis. HEK293 cells co-expressing different amounts of
AT1R-Rluc 10 ng (A), 25 ng (B), or 50 ng (C) with fixed amount of Venus-Gq, in the
absence or presence of different amounts of PAR1 (0, 5, 10, 25, 50 ng), were
stimulated or not with either 10 nM AngII, 1 U/ml, or both at 37ºC for 30 min. BRET
signals were measured. Data are means ± SEM of three independent experiments
performed in triplicate. The statistical analysis indicates the significance relative to the
response of AngII. ****p-value < 0.0001, ***p-value < 0.001, *p-value < 0.05, and
ns p-value > 0.05.
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4.3.4 Effect of Receptors Blockage on AT1R-PAR1 Heterodimerization
Next, the effect of blocking the receptors on the functional interaction between AT1R
and PAR1 and their dimerization was studied by using their antagonists for further
pharmacological investigation on Gq coupling and β-arrestin 2 recruitment. By
assessing the effect of the antagonists Irbesartan 10 µM and SCH79797 100 µM as
selective inhibitors for AT1R and PAR1, respectively with stimulation by either 10
nM AngII, 1 U/ml thrombin, or both of cells expressing AT1R-Rluc/Venus-Gq/PAR1
(Figure 17 A) and AT1R-Rluc/yPET-Arrestin 2/PAR1 (Figure 17 B). As shown in
Figure 17, Irbesartan totally blocked AT1R with both Gq (Figure 17 A) and β-arrestin
2 (Figure 17 B). However, Irbesartan also diminished thrombin signal with Gq (Figure
17 A), but not with β-arrestin. Suggesting that thrombin-mediated AT1R-Rluc/VenusGq coupling involves AT1R activation through transactivating it by PAR1, which is
consistent with the previous results. Also, SCH79797 significantly showed marked
decrease of PAR1 activity represented by diminished thrombin-induced BRET signals
with both AT1R-Rluc/Venus-Gq (Figure 17 A) coupling and AT1R-Rluc-yPETArrestin 2 recruitment (Figure 17 B) expressing cells. Interestingly, Both Irbesartan
and SCH79797 markedly diminished the BRET signal with co-treatment in both
AT1R-Rluc with either Venus-Gq or yPET-Arrestin 2 expressing cells. These results
display the significance of co-activating both PAR1 and AT1R receptors, inducing the
positive allosteric modulation of PAR1 on AT1R through transactivation.
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Figure 17: BRET analysis to assess the effect of receptors blockage on AT1R
transactivation by PAR1. HEK293 expressing either AT1R-Rluc/Venus-Gq/PAR1 (A)
or AT1R-Rluc/yPET-Arrestin 2/PAR1 (B) were first pretreated or not for 15 min at
37ºC with 10 µM Irbesartan or 100 µM SCH79797 antagonists, followed by agonists
treatment for 30 min at 37ºC with or without 10 nM AngII, 1 U/ml thrombin, or both.
BRET signals were measured in living cells and in real time. Data are means ± SEM
of four to six independent experiments performed in triplicates. The statistical analysis
indicates the significance relative to the response of AngII or thrombin alone as well
as to the condition of the combined treatment in control as indicated. ****p-value <
0.0001, ***p-value < 0.001, and ns p-value > 0.05.
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4.3.5 The Effect of AT1R-PAR1 Heterodimerization on Gαq/Inositol Phosphate
Signaling Pathway
Then, to correlate the effect of AT1R-Rluc/Venus-Gq coupling on its downstream
signaling by measuring the production and accumulation of the second messenger IP1,
the effect of co-expressing AT1R and PAR1 on the Gq/inositol phosphate pathway in
both HEK293 cells transiently expressing the receptors as well as in the human
epithelial colorectal adenocarcinoma cells (HT-29) endogenously expressing AT1R
and PAR1 [107], [108] was explored. starting with dose response analysis in HEK293
expressing either AT1R-Rluc (Figure 18 A), or PAR1 (Figure 18 B) to confirm if the
previously used 10 nM AngII and 1 U/ml thrombin doses are suitable for this protocol
as well. As demonstrated in Figure 18 A and B, the EC50 dose of AngII and the
saturating dose of thrombin are consistent with what we got in BRET dose response
experiments, also that these concentration of AngII and thrombin were able to activate
Gq signaling pathway and promote IP1 production. Then, HEK293 cells expressing
either AT1R-Rluc (Figure 18 C), PAR1 (Figure 18 D), or both (Figure 18 E), were
used to measure IP1 accumulation. Cells were pretreated or not with either 10 µM
Irbesartan or 100 µM SCH79797, followed by ligands treatment without or with 10
nM AngII, 1 U/ml thrombin, or both as shown in Figure 18. Indeed, AT1R-Rluc
expressing cells significantly lost the AngII-induced IP1 response with Irbesartan
(Figure 18 C), also PAR1 expressing cells lost the thrombin-induced IP1production
when treated with SCH79797 (Figure 18 D) (P-value < 0.0001). However, cells
expressing AT1R-Rluc showed IP1 response mediated by thrombin although no PAR1
transfection was there and it was blocked with SCH79797. This is might be due to the
endogenous expression of PARs in HEK293 cells. Whereas for PAR1 expressing cells,
no AngII-Induced IP1 production was observed at all, reflecting the specificity of
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PAR1 again. These findings are consistent with all the previous results and confirming
the specificity of the antagonists and receptors, confirming the functional coupling and
activation of Gq with AT1R and PAR1 with IP1 production. Interestingly, cells coexpressing both AT1R and PAR1along with co-activation, had a positive synergetic
effect on activating the Gq pathway with an increase in IP1 accumulation levels by ~
160% (P-value < 0.001). Also, this is consistent with the previous findings and
confirming the functional interaction between AT1R and PAR1 when both are
activated (Figure 18 E). And both antagonists fully abolished this positive synergetic
effect of the co-activation (Figure 18 E, green bars), emphasizing the importance of
AT1R and PAR1 activation in the synergetic interaction between AngII and thrombin.
In addition to this, with the blockage of one receptor, IP1 production level was not
completely inhibited, which might reflect the activation of Gq pathway by AT1R and
PAR1 monomers. Finally, HT-29 cells were used to examine AT1R-PAR1
dimerization effect as they originally express these two receptors (Figure 18 F). The
obtained data were consistent with the ones observed in HEK293 transfected cells
(Figure 18 F). Both AngII and thrombin elicited IP1 production response which was
markedly attenuated with Irbesartan and partially with SCH79797. So, the findings
with HT-29 cells as well corroborate with the previously obtained data from
transfected HEK293 cells, confirming the functional interaction between AT1R and
PAR1 when co-activated, even when they are endogenously expressed.
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Figure 18: AT1R-PAR1 heterodimerization effect on IP1 production via the Gq
signaling pathway assessed via HTFR FRET-based assay IP-One Tb kit (Cisbio
Bioassays, France). First, dose response analysis for IP1 production levels was done
for HEK293 cells expressing either AT1R-Rluc (A) or PAR1 (B). Then, HEK293 cells
expressing either AT1R-Rluc (C), PAR1 (D), or both (E) were pretreated with or
without 10 µM AngII blocker or 100 µM thrombin blocker for 15 min at 37ºC,
followed by ligands stimulation with or without 10 nM AngII, 1 U/ml thrombin, or
their combination for 30 min at 37ºC to measure IP1 production levels with these
different conditions. Finally, HT-29 cells with endogenous AT1R and PAR1 were
assessed as well for their ability to activate Gq signaling pathway and synthesize IP1
(F). Data are means ± SEM of three (for dose-response in HEK293 and antagonist data
in HT-29) or four (for antagonist data in HEK293) independent experiments performed
in triplicate. The statistical analysis indicates the significance relative to the response
of AngII or thrombin alone as well as to the condition of the combined treatment in
control as indicated. ****p-value < 0.0001, ***p-value < 0.001, **p-value < 0.01, *pvalue < 0.05, and ns p-value > 0.05.
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4.3.6 PAR1 Trans-inhibited AT1R Trafficking and Internalization
At the end, the regulation of the AT1R-PAR1 heterodimer was analyzed by assessing
its endosomal trafficking and internalization in HEK293 cells via BRET. For this, the
same previously used conditions were used, cells transiently expressing AT1R-Rluc,
with or without PAR1 overexpression, and with either the plasma membrane marker
Venus-Kras, or the endosomal markers Venus-Rabs. As demonstrated in Figure 19 A,
10 nM AngII induced decrease in the BRET signal between AT1R-Rluc and VenusKras, reflecting AT1R’s internalization. However, this response was not observed with
1 U/ml thrombin stimulation nor the co-stimulation. On the other hand, in the presence
of PAR1 overexpression along with the co-stimulation, a sharp decrease by ~60% (pvalue < 0.0001, n=3) in the BRET signal was obtained (Figure 19 A). Together, these
data clearly demonstrate that PAR1 trans-inhibits AT1R’s internalization when both
receptors are activated. Finally, the internalization findings were confirmed by further
investigation of the endosomal trafficking using HEK293 cells transiently expressing
AT1R-Rluc with either Venus-Rab5 (Figure 19 B) or Venus-Rab5 (Figure 19 C) as
endosomal markers to assess the early and late endosomal trafficking, respectively, in
the presence or absence of PAR1 overexpression. Similarly, in cells expressing AT1RRluc/Venus-Rabs, 10 nM AngII induced AT1R trafficking, but not 1 U/ml thrombin
alone (Figure 19 B, C). However, the co-activation diminished its trafficking. Again,
this effect might be due to the presence of endogenous PAR1 in HEK293 cells.
Excitingly, in the presence of PAR1, 10 nM AngII enhanced the early endosomal
trafficking by ~ 120% with Rab5(Figure 19 B). Interestingly, in the presence of PAR1
plus the co-activation, a significant decrease in the BRET signals was observed with
both Rab5 (Emax = 59 ± 2%, p-value <0.01, n=3) and Rab7 (Emax = 81 ± 6%, p-value
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< 0.1, n=3). Confirming that PAR1 negatively modulates the early and late trafficking
of AT1R. Together, these results revealed the action of PAR1 as a negative allosteric
modulator for AT1R internalization as well as trafficking when the two receptors are
activated.

Figure 19: PAR1 negatively modulated AT1R internalization and trafficking.
Transient expression of AT1R-Rluc with either Venus-Kras (A), Venus-Rab5 (B), or
Venus-Rab7 (C), in the presence or absence of PAR1 overexpression. Cells were
treated for 30 min at 37ºC with or without 10 nM AngII (blue bars), 1 U/ml thrombin
(red bars), or both (green bars). Then BRET signals were measured in live cells. Data
are means ± SEM of three independent experiments performed in triplicate. The
statistical analysis indicates the significance relative to the condition in the presence
of 10 nM of AngII. ****p-value < 0.0001, **p-value < 0.01, and ns p-value > 0.05.
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4.3.7 MAPK/ERK Pathway Activation
Then, the ability of AT1R-PAR1 heterodimer to activate the downstream signaling
MAPK/ERK pathway (Figures 20, 21, and 22) under the previously used conditions
(single versus combined treatment and single expression of AT1R or PAR1 versus
their co-expression) was examined. Also, two stimulation times were considered, 5
min (for G protein-dependent ERK1/2) and 30 minutes for (arrestin-dependent
ERK1/2) as well as two combinations of AngII and thrombin doses. 1 U/ml thrombin
elicited ERK1/2 phosphorylation regardless of the cells used, while 10 nM of AngII
showed very weak ERK1/2 phosphorylation in AT1R expressing HEK293 cells
(Figure 20 B) whereas the response was more clear in cells co-expressing AT1R-Rluc
and PAR1 (Figure 20 C). This was true for both 5 minutes and 30 minutes of
stimulation. In the combined AngII/thrombin treatment, it seems like there was a slight
potentiation at 5 minutes and a strong reduction at 30 minutes. This observation might
be consistent with the inhibition of AT1R internalization upon PAR1 co-expression
and activation (Figure 19). In Figure 21, the focus of this study was on HEK293 cells
co-expressing AT1R-Rluc and PAR1, and 5 minutes of stimulation using two
combinations of AngII and thrombin doses. In Panel A, 10 nM of AngII was combined
with 1 U/ml of thrombin and this showed a strong thrombin-mediated ERK1/2
phosphorylation and only weak response with AngII. Their combination tends to elicit
a slight potentiation. By contrast, in Panel B, the increase of AngII dose (1 uM) seems
to give more ERK1/2 response and its combination with thrombin at a lower dose (0.1
U/ml) promoted an increased ERK1/2 phosphorylation.

Finally, ERK1/2

phosphorylation was examined on endogenous receptors in HT-29 cells (Figure 22)
and as shown both thrombin (1 U/ml) and AngII (10 nM) showed ERK1/2
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phosphorylation and their combination did not have any further effect. Together these
preliminary data on ERK1/2 in HEK293 cells suggest a potentiation of ERK1/2
phosphorylation upon combined treatment with AngII and thrombin. However, they
did not bring any evidence that this was mediated by AT1R-PAR1 complex or their
functional interaction. Further investigation is required to address this aspect of AT1R
and PAR1 function and pharmacology. Therefore, these ERK1/2 data are too
preliminary and further controls, tools, and investigations are needed to better correlate
these findings and BRET data with this important downstream signaling pathway of
GPCRs.

Figure 20: Phosphorylation of ERK1/2 in HEK293 cells. HEK293 cells transiently
expressing either PAR1 (A) AT1R-Rluc (B), or both (C), were stimulated with AngII
(10 nM), thrombin (1 U/ml), or both, for 5 minutes (upper panel) or 30 minutes (lower
panel) and then lysed for SDS-PAGE followed by western blot using the mouse antiphospho-p44/42 (pERK1/2) (Cell Signaling) (1:2000 dilution). The total ERK1/2 was
detected using the primary rabbit polyclonal anti-p44/42 ERK1/2 (1:1000 dilution).
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Figure 21: Phosphorylation of ERK1/2 in HEK293 cells at two different stimulations.
HEK293 cells transiently coexpressing AT1R-Rluc and PAR1 were stimulated for 5
minutes with two different combinations of AngII and thrombin doses: 10 nM of AngII
with 1 U/ml of thrombin (A) or 1 µM of AngII with 0.1 U/ml of thrombin (B), as
indicated, and then lysed for SDS-PAGE followed by western blot using the mouse
anti-phospho-p44/42 (pERK1/2) (Cell Signaling) (1:2000 dilution). The total ERK1/2
was detected using the primary rabbit polyclonal anti-p44/42 ERK1/2 (1:1000
dilution).
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Figure 22: Phosphorylation of ERK1/2 in HT-29 cells. HT-29 were stimulated with
AngII (10 nM), thrombin (1 U/ml), or both, for 5 minutes and then lysed for SDSPAGE followed by western blot using the mouse anti-phospho-p44/42 (pERK1/2)
(Cell Signaling) (1:2000 dilution). The total ERK1/2 was detected using the primary
rabbit polyclonal anti-p44/42 ERK1/2 (1:1000 dilution).
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Chapter 5: Discussion and Conclusion

Crosstalk between AngII and thrombin in physiology and pathophysiology has been
well documented previously, but not at the pharmacological level and specifically not
at the receptor level, AT1R and PAR1, respectively. This thesis study highlighted for
the first time the pharmacological interplay between AngII and thrombin and their
respective receptors using various resonance energy transfer assays. The findings of
this research work clearly demonstrated the physical and functional interaction
between AT1R and PAR1 via forming heterodimers in vitro, revealing the positive
allosteric modulation of thrombin through PAR1 on AT1R by transactivating it and
transinhibition of its internalization and endosomal trafficking in a co-activationdependent manner (Figure 23).

Figure 23: AT1R-PAR1 heterodimerization and its functional consequences.
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The Co-IP along with the BRET saturation analysis confirmed the physical interaction
between AT1R and PAR1 by forming heterodimers in vitro as both are in close
proximity as they were immunoprecipitated together. On the other hand, the functional
consequences of AT1R-PAR1 heterodimerization were proven by dose response and
real-time kinetics analysis. This confirmed the specificity of each ligand towards its
receptor and the ability of AT1R and PAR1 monomers to activate Gq, mediating the
production of the second messenger IP1, as well as their ability to induce β-arrestin 2
recruitment (Figure 12 A, B).
The combined treatment of AngII and thrombin for cells expressing AT1R-Rluc
without or with either Gq or β-arrestin 2 and in PAR1’s absence, mediated a left shift
in the dose response (Figure 12 C, E) and induced increase in BRET signal with the
real-time kinetics (Figure 15 A, C) as well as the IP1 (Figure 18 C) analysis,
demonstrating a positive allosteric modulation effect of thrombin on AT1R. Indeed,
this effect of thrombin is not through direct binding to AT1R as demonstrated in
thrombin doses (Figure 13 A, C) by which cells expressing AT1R-Rluc without PAR1
were treated with thrombin doses did not show any BRET response. Also, this was
confirmed in the first dose response analysis (Figure 12 A, B); Ang II dose response
was achieved only with AT1R-Rluc expressing cells and similarly thrombin dose
response with PAR1-Rluc expressing cells, as well as in the antagonists analysis; when
Irbesartan blocked AT1R signal not thrombin-mediated BRET signal (Figure 17).
These results build on existing evidence of the endogenous expression of PARs in
HEK293 cells [105], [106]. Interestingly, AT1R-PAR1 heterodimerization with the
co-stimulation showed significant marked enhanced dose-dependent Gq signal
transduction mediating IP1 production (Figure 12 D, 13 B, 17 A, and 18 E) and βarrestin 2 recruitment (Figure 12 F, 13 D, 17 B, and 18 E) compared to the monomers.
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These data reflect positive allosteric modulation of thrombin activated PAR1 by
transactivating it (Figure 12 D, F) (Figure 24), as described in the speculative model
(Figure 24 C).
In addition, 1 U/ml thrombin alone for cells expressing AT1R and PAR1 with either
Gq or β-arrestin 2, induced an increase in the BRET response between AT1R-Rluc and
Gq and in a less extent with β-arrestin 2 (Figure 12 D, F, 13 B, D, 15 B, D, and 17).
These data might suggest functional selectivity towards β-arrestin 2 over Gq as the
preliminary MAPK/ERK findings showed ERK phosphorylation with 30 minutes
stimulation (Figure 20 C). Another plausible explanation is that this might be due to
conformation of BRET sensors. However, with the co-stimulation both Gq and βarrestin 2 showed similar responses.
Moreover, these data of the functional consequences of the heterodimerization occur
in a dose-dependent manner as well as in a receptor expression level-dependent
manner (Figure 16). AT1R-PAR1 heterodimer was able to couple to Gq in all the used
expression levels. However, 10 ng AT1R-Rluc (Figure 16 A) demonstrated less
positive modulation compared to the 25 and 50 ng (Figure 16 B, C, respectively). Also,
this response was seen in an increasing pattern with the increased PAR1 expression.
Thus, reflecting the coupling to Gq even at low expression level as well as the
importance of the expression level of receptors for transactivating AT1R by PAR1 and
thrombin. PAR1 expressed at 50 ng showed the highest BRET response (340% with 1
U/ml thrombin and 478% with co-treatment) compared to 25 ng PAR1 (294% with 1
U/ml thrombin and 446% with co-treatment) (P-value < 0.0001). This might be linked
to the different expression levels in the human body in different organs and under
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physiological and pathological circumstances such as overexpression in cancers and
cardiovascular diseases [27], [29], [31], [34], [35].
Also, BRET analysis with antagonists confirmed the inhibitory activity of each
antagonist of its receptor. Irbesartan completely blocked AT1R whereas SCH797979
partially, but significantly diminished PAR1’s activity (Figure 17). Moreover,
Irbesartan induced a decrease in the thrombin-mediated Gq coupling and this was not
seen with β-arrestin 2. These data suggest that AT1R activation and conformation is
needed for thrombin-mediated Gq coupling to AT1R by transactivation via PAR1.
Excitingly, both antagonists with the co-stimulation, significantly diminished Gq
coupling and β-arrestin 2 recruitment, confirming the importance of co-activating both
ATR1 and PAR1 for mediating the transactivation which requires conformational
changes in both receptors. Further studies are required to investigate the effect of
combining both blockers simultaneously to look for any change in the partial
remaining effect with SCH79797 blocking. This is due to the fact that SCH79797 is a
selective noncompetitive blocker acting on the ligand binding site, in addition to the
fact the PAR1 is activated in a unique way as described previously. These results
provide a new insight into the importance of considering this heterodimerization when
treating diseases associated with the two physiological systems and might be mediated
by the two receptors, as mostly treatment targets only one GPCR blocker [27], [34],
[109], [110]. This also has been recommended in the recent study by Hasan et al.,
which documented the role of thrombin in atrial endothelial ageing and senescence via
AT1R, and by using ARBs the response was attenuated [42]. The combination of
thrombin and AngII blockers was suggested in their study treating the observed proinflammatory, pro-thrombotic, pro-fibrotic and pro-remodeling responses [42].
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Additionally, the downstream signaling of Gq-induced IP1 production is mediated by
both monomers, AT1R and PAR1 (Figure 18 A, B). So, it was challenging to find a
way to determine if the produced IP level is by AT1R, PAR1, AT1R-PAR1 dimer, or
even by other components. In general, all the findings are consistent with the previous
results, cells expressing AT1R-Rluc activated Gq signal transduction pathway and
mediated IP1 production, and this effect was attenuated by Irbesartan (Figure 18 C).
However, a response with thrombin as well was obtained as observed previously, with
the possibility of other endogenous PARs contribution (Figure 18 C). Similarly,
thrombin treated PAR1 expressing cells mediated IP1 production and lost this response
with SCH79797 (Figure 18 D). Interestingly, cells expressing both receptors showed
remarkable synergetic increase in IP1 production levels by ~160%, and this response
was significantly diminished with each antagonist (Figure 18 E, F). However, the
inhibition of one receptor did not fully inhibit Gq-mediated production. This finding
suggests IP1 production by the monomers.
Surprisingly, PAR1 greatly influenced AT1R’s regulation through transinhibition of
its internalization and endosomal trafficking (Figure 19). Altered internalization and
endosomal trafficking has been reported in many heterodimerizations (Table 1).
Finally, these preliminary data suggest activation of MAPK pathway by
phosphorylation. Two time points were considered, 5 min for G protein and 30 min
for β-arrestin 2--mediated MAPK activation. 1 U/ml thrombin induced strong
phosphorylation in cells expressing either PAR1, AT1R-Rluc, or both (Figure 20). The
10 nM AngII induced weak phosphorylation in cells expressing AT1R-Rluc, whereas
strong activation was observed in cells co-expressing the two receptors. Moreover, costimulation in cells co-expressing AT1R-Rluc and PAR1 demonstrated stronger
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phosphorylation with 5 in stimulation, while this effect was diminished with 30 min
stimulation. This could be due to the finding in Figure 19, where AT1R’s
internalization was inhibited by PAR1 when co-stimulated. However, these data did
not bring any evidence that this was mediated by AT1R-PAR1 complex or their
functional interaction. Further investigation is required to address this aspect of AT1R
and PAR1 function and pharmacology. Therefore, it is believed that these ERK1/2
data are too preliminary and further controls, tools, and investigations are needed to
better correlate the findings and BRET data with this important downstream signaling
pathway of GPCRs. Thus, this part was not included in the revised manuscript.
Further research is needed to establish the opposite configuration for further
understanding of this heterodimerization, some data on this are being analyzed now
and are all consistent with each other. But unfortunately, due to the limited time they
are not shown in this thesis document. Also, investigation AT1R-PAR1
heterodimerization in vivo and its effects as the heterodimer in vitro cannot reach its
site of in vivo action, this will pave the way to consider all the findings in drug
discovery as well as in understanding the physiological and pathological interplay
between RAS and thrombin.
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Figure 24: Speculative model of AT1R-PAR1 interplay and its effect on AT1R activity
and regulation revealed by BRET. (A) Single AT1R activation, (B) Single PAR1
activation, and (C) Dual activation of AT1R and PAR1 [111].
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